Josep Rodés-Cabau, JoAnn Lindenfeld, William T Abraham, Michael R Zile, Saibal Kar, Antoni Bayés-Genís, Neal Eigler, Richard Holcomb, Julio Núñez, Elizabeth Lee, Michal Laufer Perl, Gil Moravsky, Michael Pfeiffer, John Boehmer, John Gorcsan, Jeroen J Bax, Stefan Anker, Gregg W Stone
AIMS: Heart failure (HF) outcomes remain poor despite optimal guideline-directed medical therapy (GDMT). We assessed safety, effectiveness, and transthoracic echocardiographic (TTE) outcomes during the 12 months after Ventura shunt implantation in the RELIEVE-HF open-label roll-in cohort. METHODS AND RESULTS: Eligibility required symptomatic HF despite optimal GDMT with ≥1 HF hospitalization in the prior year or elevated natriuretic peptides. The safety endpoint was device-related major adverse cardiovascular or neurological events at 30 days, compared to a prespecified performance goal...
April 1, 2024: European Journal of Heart Failure